HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

Shares in Verve Therapeutics ( VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly ( LLY -2.54%) to ...

Israelis lack sleep and experience high anxiety amid the wars with Hamas and Iran as the two Middle East nations exchange ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Lilly’s Verve Therapeutics bid is a boon; CDC COVID-19 official resigns in protest of RFK Jr.; Former ACIP members rebuke RFK Jr. in joint essay.

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Solar stocks tumbled after Senate Republicans maintained a full phase-out of [solar and wind-energy tax credits]( ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...